CorMedix says FDA accepts sNDA for REZZAYO as prophylaxis for invasive fungal disease under priority review

CorMedix Therapeutics says the FDA has accepted its supplemental new drug application seeking approval of REZZAYO (rezafungin) for prophylaxis of invasive fungal disease, granting priority review with a PDUFA target action date in Q1 2027.

Detected & updated continuously · Source: Nebula